NicOx: Presentation of promising preclinical results in the fields of ophthalmology and pain
SOPHIA ANTIPOLIS, FRANCE–(Marketwire – 06/01/10) – www.nicox.com NicOx S.A. (NYSE Euronext Paris: COX) today announced that two drug candidates, representing new classes of nitric oxide (NO)-donating compounds based on the Company’s NO-donating R&D platform, have moved into preclinical research with preclinical data presented at scientific conferences for the first …